Study of Lu AG13909 for adults with Cushing's disease
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests a new medicine called Lu AG13909 for adults with Cushing's disease caused by a pituitary tumor. It aims to see if the medicine can lower cortisol levels and help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with Cushing's disease caused by a pituitary tumor (confirmed by MRI, blood tests, or tumor tissue).
- Your urine cortisol levels (from at least 3 separate 24-hour collections) must be more than 1.5 times the upper limit of normal.
- If you take medicine for Cushing's, you must stop it for a washout period before the study starts.
- You cannot have severe Cushing's disease, like poorly controlled diabetes or high blood pressure, or vision problems due to a tumor pressing on the optic nerve.
- You must not have had pituitary surgery within the last 3 months or radiation therapy in the last 10 years.
- You must be willing to use effective birth control if you could become pregnant, and cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a study that collects and reviews information about how people with Cushing’s syndrome (including some mild forms and certain “silent” tumors) are diagnosed and treated, and what outcomes they have. It may help researchers understand which treatments work best in different types of the condition.
This early study tests Lu AG13909 in people with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. It aims to see how the drug affects hormone levels and whether it is safe for different CAH hormone patterns.
This study checks long-term health in people who were treated successfully for Cushing disease when they were under 21. It also collects information from family members to study genetic links to pituitary tumors.
This Phase 2 study tests seliciclib (also called R-roscovitine) in people with Cushing disease caused by a pituitary tumor and ongoing high cortisol levels. It may help reduce excess cortisol production in those whose Cushing disease has not fully gone away or has come back after standard treatment.
This study looks at how Cushing’s syndrome affects people before treatment and what changes after treatment. It may help researchers understand what to expect and improve care for adults with newly diagnosed Cushing’s syndrome.
This Phase 2 trial tests fimepinostat (a targeted cancer-style drug) to help control Cushing disease caused by a pituitary tumor. It’s mainly for adults whose Cushing is confirmed to come from the pituitary and who meet safety and medication-washout rules.
Hear when a new Cushing's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.